» Articles » PMID: 21549153

Immune Responses of Chickens Inoculated with a Recombinant Fowlpox Vaccine Coexpressing HA of H9N2 Avain Influenza Virus and Chicken IL-18

Overview
Journal Antiviral Res
Publisher Elsevier
Date 2011 May 10
PMID 21549153
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Control of the circulation of H9N2 avian influenza virus (AIV) is a major concern for both animal and public health, and H9N2 AIV poses a major threat to the chicken industry worldwide. Here, we developed a recombinant fowlpox virus (rFPV-HA) expressing the haemagglutinin (HA) gene of the A/CH/JY/1/05 (H9N2) influenza virus and a recombinant fowlpox virus (rFPV-HA/IL18) expressing the HA gene and chicken interleukin-18 (IL-18) gene. Recombinant plasmid pSY-HA/IL18 was constructed by cloning chicken IL-18 expression cassette into recombinant plasmid pSY-HA containing the HA gene. Two rFPVs were generated by transfecting two recombinant plasmids into the chicken embryo fibroblast cells pre-infected with S-FPV-017, and assessed for their immunological efficacy on one-day-old White Leghorn specific-pathogen-free chickens challenged with the A/CH/JY/1/05 (H9N2) strain. There was a significant difference in HI antibody levels (P<0.05) elicited by either rFPV-HA or rFPV-HA/IL18. The level of splenocyte proliferation response in the rFPV-HA/IL18-vaccinated group was significantly higher (P<0.05) than that in the rFPV-HA group. After challenge with 10(6.5)ELD(50) H9N2 AIV 43days after immunization, rFPVs vaccinated groups could prevent virus shedding and replication in multiple organs in response to H9N2 AIV infection, and rFPV-HA/IL18 vaccinated group had better inhibition of viruses than rFPV-HA vaccinated group. Our results show that the protective efficacy of the rFPV-HA vaccine could be enhanced significantly by simultaneous expression of IL-18.

Citing Articles

Spray vaccination with a safe and bivalent H9N2 recombinant chimeric NDV vector vaccine elicits complete protection against NDV and H9N2 AIV challenge.

Wang X, Dai J, Yang W, Yao Y, Zhang J, Liu K Vet Res. 2025; 56(1):24.

PMID: 39891242 PMC: 11786375. DOI: 10.1186/s13567-025-01448-5.


M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge.

Calzas C, Alkie T, Suderman M, Embury-Hyatt C, Khatri V, Le Goffic R NPJ Vaccines. 2024; 9(1):161.

PMID: 39237609 PMC: 11377767. DOI: 10.1038/s41541-024-00944-7.


Mass vaccination with reassortment-impaired live H9N2 avian influenza vaccine.

Cargnin Faccin F, Caceres C, Gay L, Seibert B, van Bentem N, Rodriguez L NPJ Vaccines. 2024; 9(1):136.

PMID: 39097573 PMC: 11297921. DOI: 10.1038/s41541-024-00923-y.


Current Status of Poultry Recombinant Virus Vector Vaccine Development.

Wang H, Tian J, Zhao J, Zhao Y, Yang H, Zhang G Vaccines (Basel). 2024; 12(6).

PMID: 38932359 PMC: 11209050. DOI: 10.3390/vaccines12060630.


Efficacy of Fowlpox Virus Vector Vaccine Expressing VP2 and Chicken Interleukin-18 in the Protection against Infectious Bursal Disease Virus.

Eldaghayes I, Rothwell L, Skinner M, Dayhum A, Kaiser P Vaccines (Basel). 2023; 11(11).

PMID: 38006048 PMC: 10675466. DOI: 10.3390/vaccines11111716.